Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

Infertility in Males

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multidisciplinary Cancer Care Model: A Positive Association Between Oncology Nurse Navigation and Improved Outcomes for Patients With Cancer.

Clinical journal of oncology nursing·2018

Same author

Query About the Frequency of Biopsy Complications.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2016

Same author

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

International journal of radiation oncology, biology, physics·2014

Same author

Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review.

International journal of urology : official journal of the Japanese Urological Association·2014

Same author

A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.

American journal of clinical oncology·2012

Same author

Durable, complete remission with bevacizumab-based chemotherapy in a patient with metastatic gastroesophageal junction cancer.

Gastrointestinal cancer research : GCR·2012

Same journal

The use of natural language processing in predictive toxicology.

Expert opinion on drug metabolism & toxicology·2026

Same journal

An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.

Expert opinion on drug metabolism & toxicology·2026

Same journal

Optimizing tamoxifen therapy in breast cancer: a narrative review of dose escalation in patients with CYP2D6 polymorphisms.

Expert opinion on drug metabolism & toxicology·2026

Same journal

Effect of concomitant rifampin and clarithromycin on elexacaftor-tezacaftor-ivacaftor using a physiologically based pharmacokinetic (PBPK) modeling approach.

Expert opinion on drug metabolism & toxicology·2026

Same journal

Gastrointestinal bleeding risk among antithrombotics users: a propensity score matched study of drug classes.

Expert opinion on drug metabolism & toxicology·2026

Same journal

Complex <i>in vitro</i> model developers' perspective on advanced hepatic <i>in vitro</i> culture methods for predictive drug safety.

Expert opinion on drug metabolism & toxicology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

Finasteride.

Uzair B Chaudhary¹, Jeffrey S Turner

¹UCSF/Fresno Medical Education Program, 2823 Fresno Street, Internal Medicine, Suite A, Fresno, CA 93721, USA. uchaudhary@fresno.ucsf.edu

Expert Opinion on Drug Metabolism & Toxicology

|June 12, 2010

Summary

This summary is machine-generated.

Finasteride, a 5-alpha-reductase inhibitor, was the first agent to reduce prostate cancer prevalence. However, concerns about high-grade cancer incidence limit its clinical use for chemoprevention.

More Related Videos

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Related Experiment Videos

Last Updated: Jun 12, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Area of Science:

Oncology
Urology
Preventive Medicine

Background:

Prostate cancer is a prevalent malignancy in males, with chemoprevention offering a promising strategy.
The long latency and hormonal responsiveness of prostate cancer make it a target for preventive therapies.

Purpose of the Study:

To review the development and efficacy of finasteride as a prostate cancer chemopreventive agent.
To discuss the Prostate Cancer Prevention Trial (PCPT) findings and controversies surrounding finasteride use.

Main Methods:

Review of the Prostate Cancer Prevention Trial (PCPT) data.
Analysis of finasteride's role in prostate cancer chemoprevention.
Discussion of alternative chemopreventive agents and ongoing research.

Main Results:

Finasteride demonstrated a reduction in overall prostate cancer prevalence.
A higher incidence of high-grade prostate cancer was observed in the finasteride arm.
Finasteride is generally well-tolerated but its use is limited by safety concerns.

Conclusions:

Finasteride, a 5-alpha-reductase inhibitor, offers a benefit in reducing prostate cancer prevalence.
Concerns regarding high-grade cancer incidence have hindered finasteride's widespread adoption in clinical practice.
Finasteride is not approved as a chemopreventive agent due to risk-benefit considerations.